On November 5, 2015 Cellectis (Alternext: ALCLS – Nasdaq: CLLS) reported that data on its engineered allogeneic CAR T-Cell product candidates, UCARTCS1 and UCART123, will be presented during the 2015 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Cellectis, NOV 5, 2015, View Source [SID:1234508042]). A poster and an oral presentation will be presented during this event.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa/CS1 Double Knockout T-Cells for the Treatment of Multiple Myeloma (MM)
Oral presentation
Session Name: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immunotherapeutics and the Impact of the Microenvironment
Presentation Time: Saturday, December 5, 2015 at 2:15 PM
TCRab Deficient CAR T-Cells Targeting CD123: An Allogeneic Approach of Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia (AML)
Poster presentation
Session Name: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Presentation Time: Sunday, December 6, 2015 from 6:00 PM to 8:00 PM